IPO Boutique Research, Color & More Information for Subscribers
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Adamas Pharmaceuticals, Inc. Symbol: ADMS Price: Last trade $27.91 Trade Date: 1/7 Shares: 2.5 million Underwriter(s) Cowen & Co., Piper Jaffray[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Cerulean Pharma Inc. Symbol: CERU Price: Last trade $7.25 Trade Date: 4/7 Shares: 4.8 million Underwriter(s) Leerink Partner, Barclays Capital Co[…]